Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons

Topic: Disease mechanisms in lab and animal studies

Amyloid-beta (Aβ) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease (AD). However, the loss of synapses and dysfunctions of neurotransmission are more directly tied to disease severity. The role of these lesions in the pathoetiological progression of the disease remains contested. Biochemical, cellular, molecular, and pathological studies provided several lines of evidence and improved our understanding of how Aβ and hyperphosphorylated tau accumulation may directly harm synapses and alter neurotransmission. In vitro evidence suggests that Aβ and hyperphosphorylated tau have both direct and indirect cytotoxic effects that affect neurotransmission, axonal transport, signaling cascades, organelle function, and immune response in ways that lead to synaptic loss and dysfunctions in neurotransmitter release. Observations in preclinical models and autopsy studies support these findings, suggesting that while the pathoetiology of positive lesions remains elusive, their removal may reduce disease severity and progression. The purpose of this article is to highlight the need for further investigation of the role of tau in disease progression and its interactions with Aβ and neurotransmitters alike.

Key findings

• In vitro evidence suggests that Aβ and hyperphosphorylated tau have both direct and indirect cytotoxic effects that affect neurotransmission, axonal transport, signaling cascades, organelle function, and immune response in ways that lead to synaptic loss and dysfunctions in neurotransmitter release.
• Observations in preclinical models and autopsy studies support these findings, suggesting that while the pathoetiology of positive lesions remains elusive, their removal may reduce disease severity and progression.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.3233/jad-160612
• PubMed: 27567878
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{rajmohan2017-27567878,
  author  = {Rajmohan, R. and Reddy, P. H.},
  title   = {{Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2017},
  doi     = {10.3233/jad-160612},
  pmid    = {27567878},
  url     = {https://doi.org/10.3233/jad-160612}
}

Related studies in Disease mechanisms

• The intersection of amyloid beta and tau at synapses in Alzheimer's disease Neuron · 2014-05-01 · usefulness score 36/100
• Optineurin deficiency disrupts phosphorylated tau proteostasis and clusterin expression in human neurons Acta neuropathologica communications · 2025-09-02 · usefulness score 43/100
• Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain Journal of Neuroscience · 2004-04-07 · usefulness score 40/100
• Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks Nature neuroscience · 2010-07-01 · usefulness score 40/100
• Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses Nature neuroscience · 2009-12-01 · usefulness score 40/100
• beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons The Journal of biological chemistry · 2006-07-24 · usefulness score 36/100

Also tagged “phosphorylation”

387 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 387 tagged studies.

• P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy Neuron · 2024-03-20 · usefulness score 43/100 · Biomarkers
• Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice Journal of neurochemistry · 2014-08-01 · usefulness score 36/100 · Drug development
• Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons Neuroscience research · 1998-08-01 · usefulness score 36/100 · Drug development

Similar studies

• The role of pathological tau in synaptic dysfunction in Alzheimer's diseases 2021 · Disease mechanisms
• Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease 2021 · Inflammation and the immune system
• Synaptic tau: A pathological or physiological phenomenon? 2021 · Disease mechanisms
• Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease 2017 · Drug development
• Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration 2010 · Disease mechanisms
• Understanding Tau pathology: Insights from animal models 2025 · Drug development

More on Disease mechanisms

• A review that covers this ground Dysbiosis and Alzheimer's Disease: Cause or Treatment Opportunity? Cellular and molecular neurobiology · 2021-01-05 · usefulness score 41/100
• Newest in this subject Aβ42 oligomers disrupt calcium homeostasis via Piezo1 and induce neurotoxicity in differentiated SH-SY5Y cells Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Neuronal Hyperactivity Induces Tau Phosphorylation Selectively in Excitatory Pyramidal Neurons Which Contributes to GluA2 Regulation bioRxiv · 2026-10-28 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Disease mechanisms →